Diabetic Cardiomyopathies

Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.

Also Known As:

Networked: 652 relevant articles (44 outcomes, 110 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Fibrosis (Cirrhosis)
2.	Inflammation
3.	Heart Failure
4.	Cardiomegaly (Heart Hypertrophy)
5.	Hypertension (High Blood Pressure)

Experts

1.	Cai, Lu: 22 articles (12/2015 - 01/2003)
2.	Zhang, Yun: 16 articles (05/2015 - 01/2006)
3.	Ren, Jun: 15 articles (02/2015 - 07/2002)
4.	Tan, Yi: 10 articles (12/2015 - 06/2009)
5.	Tschöpe, Carsten: 10 articles (06/2012 - 10/2002)
6.	Kelly, Darren J: 9 articles (01/2015 - 11/2007)
7.	Turan, Belma: 9 articles (12/2013 - 12/2002)
8.	Schultheiss, Heinz-Peter: 9 articles (04/2010 - 12/2002)
9.	Zhang, Wei: 8 articles (06/2014 - 01/2006)
10.	Epstein, Paul N: 8 articles (02/2013 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Diabetic Cardiomyopathies:

1.	Streptozocin (Streptozotocin)FDA Link 01/01/2015 - "The goal of this study was to determine if enhanced skeletal muscle expression of EcSOD is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy. " 01/01/2012 - "This study was designed to evaluate the impact of ALDH2 on streptozotocin-induced diabetic cardiomyopathy. " 02/01/2009 - "Our study aimed to test the hypothesis that overexpression of ANT1 in cardiomyocytes has cardioprotective effects in diabetic cardiomyopathy induced by streptozotocin (STZ). " 04/01/2003 - "This study was conducted to investigate the effect of Omega-3 PUFA on streptozotocin (STZ)-induced diabetic cardiomyopathy in wistar rats. " 08/01/2015 - "We investigated whether silencing of miR-195 reduces diabetic cardiomyopathy in a mouse model of streptozotocin (STZ)-induced type 1 diabetes. "
2.	Glucose (Dextrose)FDA LinkGeneric 04/01/2013 - "We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high glucose-treated H9c2 cardiac myoblast cells. " 09/01/2013 - "Thus, agents that suppress glucose-induced intracellular ROS levels can have therapeutic potential against diabetic cardiomyopathy. " 06/10/2015 - "Given the multifactorial development and progression of diabetic cardiomyopathy, traditional treatments such as anti-diabetic agents, as well as cellular and mitochondrial fatty acid uptake inhibitors aimed at shifting the balance of cardiac metabolism from utilizing fat to glucose may not adequately target all aspects of this condition. " 06/10/2015 - "Metabolic disturbances such as altered lipid handling and substrate utilization, decreased mechanical efficiency, mitochondrial dysfunction, disturbances in nonoxidative glucose pathways, and increased oxidative stress are hallmarks of diabetic cardiomyopathy. " 01/01/2015 - "High concentrations of glucose induce cardiomyocyte apoptosis, and contribute to diabetic cardiomyopathy. "
3.	Insulin (Novolin)FDA Link 01/01/2012 - "In this experimental model of diabetic cardiomyopathy, CoPP treatment improved both cardiac function and coronary flow by blunting oxidative stress, restoring eNOS/iNOS expression balance and increasing HO-1 levels, thereby favoring improvement in both endothelial function and insulin sensitivity." 07/01/1996 - "Studies were performed in the acute (8 days) and chronic (63 days) phase of development of insulin-dependent diabetic cardiomyopathy. " 05/01/2015 - "This review summarizes our current understanding of how defective insulin signaling impacts cardiac function in diabetic cardiomyopathy and discusses the potential role of mitochondrial dynamics. " 05/01/2015 - "However, comprehensive understanding of molecular mechanisms linking insulin signaling and changes in the architecture of the mitochondrial network in diabetic cardiomyopathy is lacking. " 05/01/2015 - "Defective insulin signaling and mitochondrial dynamics in diabetic cardiomyopathy."
4.	Sirtuin 3IBA 01/01/2015 - "Our previous study shows that apelin (APLN) increases Sirtuin 3 (Sirt3) expression and ameliorates diabetic cardiomyopathy. " 02/15/2014 - "Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3."
5.	triptolideIBA 01/01/2013 - "Our data demonstrate that anti-inflammatory effects of triptolide involving the NF-κB signaling pathway can improve left ventricular function under diabetic conditions, suggesting triptolide treatment might be beneficial in diabetic cardiomyopathy." 01/01/2013 - "Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy." 01/01/2015 - "Triptolide treatment leads to an improvement in Diabetic Cardiomyopathy (DCM) in streptozotocin-induced diabetic rat model. " 01/01/2015 - "Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats." 01/01/2013 - "Given the importance of inflammation in the onset and progression of diabetic cardiomyopathy, we investigated the potential protective effects of triptolide, an anti-inflammatory agent, in streptozotocin-induced diabetic rat model and in H9c2 rat cardiac cells exposed to high glucose. "
6.	Proteins (Proteins, Gene)IBA 01/01/2014 - "This study investigated the effects of alterations in Ca2+ homeostasis and sarcoplasmic reticulum Ca2+-associated proteins on cardiac function in the development of diabetic cardiomyopathy. " 11/01/1997 - "The present study is devoted to elucidation of molecular alterations, particularly those induced by non-enzymatic glycation of proteins, that may be responsible for iCaT of the rat hearts in the stage of fully developed, but still compensated diabetic cardiomyopathy (DH). " 09/06/2013 - "Our results suggest that increases in sEH and antioxidative programming are key factors in the development of type 1 diabetic cardiomyopathy in Akita mice and reveal several other proteins whose expression may be important in this complex pathophysiology. " 09/06/2013 - "Hearts from 5 week old mice were analyzed with a rigorous label-free quantitative proteomic approach to identify proteins that may play a critical role in the early pathophysiology of diabetic cardiomyopathy. " 03/01/2012 - "Here, we set out to evaluate a possible role of FoxO proteins in diabetic cardiomyopathy. "
7.	CalciumIBA 01/01/2013 - "Altered calcium homeostasis may not be the primary defect in diabetic cardiomyopathy. " 01/01/2013 - "Intracellular calcium (Ca²⁺) coordinates the cardiac contraction cycle and is dysregulated in diabetic cardiomyopathy. " 06/01/2012 - "For a better understanding of diabetic cardiomyopathy and necessary treatment strategy, several pathological mechanisms such as impaired calcium handling and increased oxidative stress, have been proposed through clinical and experimental observations. " 11/01/2008 - "It is currently unclear whether increasing SERCA2a activity in hearts with existing diabetic cardiomyopathy could still improve calcium flux and contractile performance. " 11/01/2008 - "Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy."
8.	Angiotensin IIIBA 11/01/2008 - "The objective of this study was to clarify the relationship between angiotensin II and the pathogenesis of diabetic cardiomyopathy by observing the effects of related drugs on diabetic cardiomyopathy in rats. " 11/01/2008 - "Preventing the increase in angiotensin II or the action of angiotensin II on its receptor can prevent the occurrence and development of diabetic cardiomyopathy." 11/01/2007 - "Given the over-expression of angiotensin II in human diabetic cardiomyopathy, we hypothesized that combining hyperglycaemia with an enhanced tissue renin-angiotensin system would lead to the development of diastolic dysfunction with adverse remodeling in a rodent model. " 01/01/2005 - " has been hypothesized that the angiotensin II (Ang II) signalling pathway may also play a role in the development of diabetic cardiomyopathy. " 05/01/2012 - "Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy."
9.	ZincIBA 01/31/2006 - "The present study therefore explored whether zinc supplementation can protect against diabetic cardiomyopathy through cardiac MT induction. " 01/01/2015 - "Effect and mechanisms of zinc supplementation in protecting against diabetic cardiomyopathy in a rat model of type 2 diabetes." 01/01/2013 - "The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy." 10/15/2012 - "Zinc (Zn) supplementation of animals and humans has been shown to ameliorate oxidative stress induced by diabetic cardiomyopathy. " 01/01/2012 - "It has been reported previously that diabetic cardiomyopathy can be inhibited or reverted with chronic zinc supplementation. "
10.	Trimetazidine (Vastarel)IBA 05/01/2010 - "Furthermore, our study suggests that trimetazidine suppresses the development of diabetic cardiomyopathy, which warrants further clinical investigation." 11/28/2003 - "Aim of the present study was to evaluate whether the metabolic effect of trimetazidine on left ventricular function in patients with diabetic cardiomyopathy. " 02/01/2011 - "Therefore, instead of routine administration of trimetazidine for the treatment of diabetic cardiomyopathy, we hypothesize that the early application of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. " 02/01/2011 - "Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy." 05/01/2010 - "To investigate the influence of trimetazidine, which is known to be an antioxidant and modulator of metabolism, on cardiac function and the development of diabetic cardiomyopathy in db/db mouse. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 06/01/2009 - "Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients." 01/01/2004 - "Despite diabetic cardiomyopathy, the pharmacologic treatment of heart failure in diabetic patients is similar to that in patients without diabetes, and in general, the clinical response of diabetic patients to drug therapies for heart failure is similar, if not superior, to that of nondiabetic patients. " 01/01/2014 - "Whereas targeting glycemic control and treating additional risk factors, such as obesity, dyslipidemia, and hypertension, are mandatory to reduce chronic complications and prolong life expectancy in diabetic patients, drug therapy tailored to reducing the deleterious effects of the AGE-RAGE interactions is being actively investigated and showing signs of promise in treating diabetic cardiomyopathy and associated heart failure. " 06/01/2015 - "Preclinical studies have provided convincing evidence that resveratrol has beneficial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia, chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. "
2.	Synchrotrons 03/05/2013 - "Using synchrotron radiation small-angle x-ray scattering, this study investigated in the in situ heart and in real-time whether changes in cross-bridge disposition and myosin interfilament spacing underlie the early development of diabetic cardiomyopathy. "
3.	Transplantation (Transplant Recipients) 02/01/2008 - "However, there is no report about the therapeutic potency of MSC transplantation on diabetic cardiomyopathy (DCM), an important cause of heart failure. " 01/01/2014 - "Our findings suggested that transplantation of bone marrow mesenchymal stem cells could inhibit the myocardial apoptosis in diabetic cardiomyopathy, possibly by up-regulating the expression of 14-3-3 protein and inhibiting the phosphorylation of Ask1." 01/01/2008 - "Diabetic cardiomyopathy is partially treatable with insulin; however, a combination of SMC transplantation and insulin treatment produced the best functional result. "
4.	Intraperitoneal Injections 05/01/2015 - "Rats were injected with a single intraperitoneal injection of STZ (55 mg/kg body weight) to induced diabetic cardiomyopathy. " 01/01/2014 - "(1) Rat model of diabetic cardiomyopathy was made by feeding rats with high fat/high sugar diet and intraperitoneal injection of small dose of streptozocin (STZ). " 07/01/2007 - "We established type 1 diabetic rat model with STZ intraperitoneal injection, used echocardiographic evaluation, hematoxylin-eosin staining and the terminal deoxynucleotidyl transferase-mediated DNA nick-end labeling staining to identify the existence of diabetic cardiomyopathy and enhanced apoptosis in the diabetic heart. "
5.	Heart Transplantation (Grafting, Heart) 03/01/2015 - "Finally, the involvement of purinergic signalling and its therapeutic potential in cardiac pathophysiology is reviewed, including acute and chronic heart failure, ischemia, infarction, arrhythmias, cardiomyopathy, syncope, hypertrophy, coronary artery disease, angina, diabetic cardiomyopathy, as well as heart transplantation and coronary bypass grafts. " 02/01/2006 - "Overactivation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) contributes to the development of cell dysfunction and tissue injury in various pathophysiological conditions associated with oxidative and nitrosative stress, including myocardial reperfusion injury, heart transplantation, diabetic cardiomyopathy and chronic heart failure. "